KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
1.500
-0.050 (-3.23%)
Oct 10, 2025, 11:09 AM EDT - Market open
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
10.53M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
Dec 31, 2019 | 6.07M | - | - |
Dec 31, 2018 | - | - | - |
Dec 31, 2017 | - | - | - |
Dec 31, 2016 | - | - | - |
Dec 31, 2015 | 45.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
KALA News
- 10 days ago - Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday? - Benzinga
- 2 months ago - KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 3 months ago - KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - GlobeNewsWire
- 4 months ago - KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 8 months ago - KALA BIO Announces Chief Executive Officer Transition - GlobeNewsWire
- 10 months ago - KALA BIO Announces $10,750,000 Private Placement - GlobeNewsWire
- 11 months ago - KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire